Evaluation of a Sustained-Release Formulation of Buprenorphine for Analgesia in Rats

Preventing and minimizing pain in laboratory animals is a basic tenet of biomedical research and is warranted for ethical, legal, and scientific reasons. Postoperative analgesia is an important facet of pain management. A sustained-release formulation of buprenorphine was tested in rats for analgesi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Association for Laboratory Animal Science 2011-03, Vol.50 (2), p.198-204
Main Authors: Foley, Patricia L, Liang, Haixiang, Crichlow, Andrew R
Format: Article
Language:English
Subjects:
Analgesia - methods
Analgesia - veterinary
Analgesics, Opioid - blood
Analgesics, Opioid - pharmacology
Animals
Buprenorphine - blood
Buprenorphine - pharmacology
Delayed-Action Preparations - pharmacology
Drug Combinations
Experimental Use
Injections, Subcutaneous - veterinary
Male
Pain Measurement - veterinary
Pain, Postoperative - drug therapy
Pain, Postoperative - veterinary
Rats
Rats, Sprague-Dawley
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preventing and minimizing pain in laboratory animals is a basic tenet of biomedical research and is warranted for ethical, legal, and scientific reasons. Postoperative analgesia is an important facet of pain management. A sustained-release formulation of buprenorphine was tested in rats for analgesic efficacy and plasma concentration over a 72-h time period. Rats were injected subcutaneously with either 1.2 mg/kg sustained-release formulation (Bup-SR), 0.2 mL/kg buprenorphine HCl (Bup-HCl), or an equivalent volume of sustained-release vehicle and tested in a thermal nociception model or a surgical postoperative pain model. In both models, Bup-SR showed evidence of providing analgesia for 2 to 3 d. Thermal latency response in rats that received the sustained-release formulation increased 28.4% and 15.6% compared with baseline values on days 1 and 2, respectively. Rats with a unicortical tibial defect and treated with Bup-SR showed similar willingness to bear weight on the hindlimbs as did negative-control animals (no surgery), demonstrated by counting vertical raises; rats treated with Bup-HCl had significantly fewer vertical raises than did control rats for 5 d after surgery. Plasma concentrations of buprenorphine remained over 1 ng/mL for 72 h after a single dose of Bup-SR. Taken together, the results indicate that this formulation of buprenorphine may be a viable option for treating postsurgical pain in laboratory rats.
ISSN:1559-6109
2769-6677